Targeting Pancreatic Cancer with Novel Nicolaioidesin C Derivatives: Molecular Mechanism, In Vitro , and In Vivo Evaluations
Journal of Medicinal Chemistry · 2024
DOI: 10.1021/acs.jmedchem.4c01141 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2024. Verfasst von Takeyoshi Yamazaki und 9 weiteren Autor:innen. Beteiligte Einrichtung: Natural Drug Discovery Laboratory, Institute of Natural Medicine, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan. Hauptthemen laut MEDLINE: Deoxycytidine, Gemcitabine, Pancreatic Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science, University of Toyama.
Abstract (Originalsprache)
Pancreatic cancer, one of the deadliest cancers with the lowest 5-year survival rate, often develops resistance to gemcitabine-based chemotherapies. The hypovascular nature of pancreatic tumors forces cancer cells to adapt to nutrient-depleted tumor microenvironments. Conventional anticancer agents targeting rapidly dividing cancer cells under nutrient-rich conditions are largely ineffective against adapted pancreatic cancer cells. Thus, targeting cancer cells under nutrient starvation, termed the "antiausterity strategy", may be effective for pancreatic cancer. This study examined nicolaioidesin C (Nic-C) derivatives as antiausterity agents. Among the 32 derivatives, Nic-15 (4n) exhibited superior cytotoxicity against MIA PaCa-2 and PANC-1 pancreatic cancer cells, inhibited MIA PaCa-2 cell migration and colony formation, and modulated the PI3K/Akt/mTOR pathway, while reducing the ER stress markers induced by gemcitabine. Nic-15 was found to inhibit tumor growth and enhance the efficacy of gemcitabine in an in vivo xenograft model. Nic-15 in combination with gemcitabine may be an effective strategy for the treatment of pancreatic cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Natural Drug Discovery Laboratory, Institute of Natural Medicine, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan.
- Department of Surgery and Science, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama 930-0194, Japan.
- Graduate School of Pharma-Medical Sciences, University of Toyama, Toyama 930-8555, Japan.
- Faculty of Engineering, University of Toyama, Toyama 930-8555, Japan.
- Graduate School of Science and Engineering, University of Toyama, Toyama, 930-8555, Japan.
ORCID-Profile: Takuya Okada, Naoki Toyooka, Tsutomu Fujii, Suresh Awale
Förderung
- Japan Society for the Promotion of Science
- University of Toyama
Zitieren
APA
Yamazaki, T., Phan, N. D., Maneenet, J., Yamagishi, M., Nishikawa, Y., Okada, T., Okumura, T., Toyooka, N., Fujii, T., & Awale, S. (2024). Targeting Pancreatic Cancer with Novel Nicolaioidesin C Derivatives: Molecular Mechanism, In Vitro , and In Vivo Evaluations. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c01141
Vancouver
Yamazaki T, Phan ND, Maneenet J, Yamagishi M, Nishikawa Y, Okada T, et al. Targeting Pancreatic Cancer with Novel Nicolaioidesin C Derivatives: Molecular Mechanism, In Vitro , and In Vivo Evaluations. Journal of Medicinal Chemistry. 2024. doi:10.1021/acs.jmedchem.4c01141
BibTeX
@article{Yamazaki2024,
author = {Yamazaki, Takeyoshi and Phan, Nguyen Duy and Maneenet, Juthamart and Yamagishi, Mitsuki and Nishikawa, Yuya and Okada, Takuya and Okumura, Tomoyuki and Toyooka, Naoki and Fujii, Tsutomu and Awale, Suresh},
title = {Targeting Pancreatic Cancer with Novel Nicolaioidesin C Derivatives: Molecular Mechanism, In Vitro , and In Vivo Evaluations},
journal = {Journal of Medicinal Chemistry},
year = {2024},
doi = {10.1021/acs.jmedchem.4c01141}
}
EUVIMED